Functional heterogeneity of genetically defined subclones in acute myeloid leukemia

Cancer Cell

Volumn 25, Issue 3, 2014, Pages 379-392

  Klco, Jeffery M ^a   Spencer, David H ^a   Miller, Christopher A ^a   Griffith, Malachi ^a   Lamprecht, Tamara L ^a   O'Laughlin, Michelle ^a   Fronick, Catrina ^a   Magrini, Vincent ^a   Demeter, Ryan T ^a   Fulton, Robert S ^a   Eades, William C ^a   Link, Daniel C ^a   Graubert, Timothy A ^a   Walter, Matthew J ^a   Mardis, Elaine R ^a   Dipersio, John F ^a   Wilson, Richard K ^a   Ley, Timothy J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CANCER PATIENT; CELL CLONE; CELL POPULATION; CONTROLLED STUDY; CYTOARCHITECTURE; ENGRAFTMENT; FUNCTIONAL GENOMICS; GENE SEQUENCE; GENE TARGETING; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR XENOGRAFT; MOLECULAR CLONING; TUMOR ENGRAFTMENT;

MUS;

ANIMALS; BASE SEQUENCE; CLONAL EVOLUTION; GENETIC VARIATION; GENOME; GENOTYPE; HETEROGRAFTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASM TRANSPLANTATION; SEQUENCE ANALYSIS, DNA;

EID: 84896081834     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.01.031     Document Type: Article

References (48)

1. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., Kempski H., Moorman A.V., Titley I., Swansbury J., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
2. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
3. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N.Engl. J. Med. 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
4. Clappier E., Gerby B., Sigaux F., Delord M., Touzri F., Hernandez L., Ballerini P., Baruchel A., Pflumio F., Soulier J. Clonal selection in xenografted human Tcell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J.Exp. Med. 2011, 208:653-661.
5. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., Harris C.C., McLellan M.D., Fulton R.S., Fulton L.L., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
6. Ding L., Ley T.J., Larson D.E., Miller C.A., Koboldt D.C., Welch J.S., Ritchey J.K., Young M.A., Lamprecht T., McLellan M.D., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
7. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
8. Gupta P.B., Fillmore C.M., Jiang G., Shapira S.D., Tao K., Kuperwasser C., Lander E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
9. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
10. Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., Traver D., van Rooijen N., Weissman I.L. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
11. Jan M., Snyder T.M., Corces-Zimmerman M.R., Vyas P., Weissman I.L., Quake S.R., Majeti R. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci. Transl. Med. 2012, 4:149ra118.
12. Jilani I., Estey E., Manshuri T., Caligiuri M., Keating M., Giles F., Thomas D., Kantarjian H., Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia 2003, 17:114-119.
13. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., Guthridge M.A., Thomas D., Barry E.F., Boyd A., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
14. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
15. Klco J.M., Spencer D.H., Lamprecht T.L., Sarkaria S.M., Wylie T., Magrini V., Hundal J., Walker J., Varghese N., Erdmann-Gilmore P., et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 2013, 121:1633-1643.
16. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M., Ng K., Ma J., Wienholds E., Dunant C., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339:543-548.
17. Krönke J., Schlenk R.F., Jensen K.O., Tschürtz F., Corbacioglu A., Gaidzik V.I., Paschka P., Onken S., Eiwen K., Habdank M., et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J.Clin. Oncol. 2011, 29:2709-2716.
18. Krönke J., Bullinger L., Teleanu V., Tschürtz F., Gaidzik V.I., Kühn M.W., Rücker F.G., Holzmann K., Paschka P., Kapp-Schwörer S., et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013, 122:100-108.
19. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
20. Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
21. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., Kandoth C., Payton J.E., Baty J., Welch J., et al. DNMT3A mutations in acute myeloid leukemia. N.Engl. J. Med. 2010, 363:2424-2433.
22. Li S., Shen D., Shao J., Crowder R., Liu W., Prat A., He X., Liu S., Hoog J., Lu C., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013, 4:1116-1130.
23. Losman J.A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., Cowley G.S., Root D.E., Ebert B.L., Kaelin W.G. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
24. Ma W., Kantarjian H., Zhang X., Jilani I., Sheikholeslami M.R., Donahue A.C., Ravandi F., Estey E., O'Brien S., Keating M., et al. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloidleukemia: clinical significance and implications. Cancer Biomark. 2009, 5:51-58.
25. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N.Engl. J. Med. 2009, 361:1058-1066.
26. McDermott S.P., Eppert K., Lechman E.R., Doedens M., Dick J.E. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 2010, 116:193-200.
27. Miyamoto T., Weissman I.L., Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl. Acad. Sci. USA 2000, 97:7521-7526.
28. Navin N., Krasnitz A., Rodgers L., Cook K., Meth J., Kendall J., Riggs M., Eberling Y., Troge J., Grubor V., et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010, 20:68-80.
29. Nik-Zainal S., Van Loo P., Wedge D.C., Alexandrov L.B., Greenman C.D., Lau K.W., Raine K., Jones D., Marshall J., Ramakrishna M., et al. The life history of 21 breast cancers. Cell 2012, 149:994-1007. Breast Cancer Working Group of the International Cancer Genome Consortium.
30. Notta F., Mullighan C.G., Wang J.C., Poeppl A., Doulatov S., Phillips L.A., Ma J., Minden M.D., Downing J.R., Dick J.E. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
31. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
32. Potter N.E., Ermini L., Papaemmanuil E., Cazzaniga G., Vijayaraghavan G., Titley I., Ford A., Campbell P., Kearney L., Greaves M. Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res. 2013, 23:2115-2125.
33. Rohle D., Popovici-Muller J., Palaskas N., Turcan S., Grommes C., Campos C., Tsoi J., Clark O., Oldrini B., Komisopoulou E., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
34. Sanchez P.V., Perry R.L., Sarry J.E., Perl A.E., Murphy K., Swider C.R., Bagg A., Choi J.K., Biegel J.A., Danet-Desnoyers G., Carroll M. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009, 23:2109-2117.
35. Sarry J.E., Murphy K., Perry R., Sanchez P.V., Secreto A., Keefer C., Swider C.R., Strzelecki A.C., Cavelier C., Récher C., et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J.Clin. Invest. 2011, 121:384-395.
36. Schmitz M., Breithaupt P., Scheidegger N., Cario G., Bonapace L., Meissner B., Mirkowska P., Tchinda J., Niggli F.K., Stanulla M., et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 2011, 118:1854-1864.
37. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., Delaney A., Gelmon K., Guliany R., Senz J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
38. Shlush L.I., Chapal-Ilani N., Adar R., Pery N., Maruvka Y., Spiro A., Shouval R., Rowe J.M., Tzukerman M., Bercovich D., et al. Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability. Blood 2012, 120:603-612.
39. Smith A.E., Mohamedali A.M., Kulasekararaj A., Lim Z., Gäken J., Lea N.C., Przychodzen B., Mian S.A., Nasser E.E., Shooter C., et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010, 116:3923-3932.
40. Smith C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., Perl A.E., Travers K.J., Wang S., Hunt J.P., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
41. Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavaré S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 2013, 110:4009-4014.
42. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012, 72:4875-4882.
43. Taussig D.C., Miraki-Moud F., Anjos-Afonso F., Pearce D.J., Allen K., Ridler C., Lillington D., Oakervee H., Cavenagh J., Agrawal S.G., et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008, 112:568-575.
44. Walter M.J., Shen D., Ding L., Shao J., Koboldt D.C., Chen K., Larson D.E., McLellan M.D., Dooling D., Abbott R., et al. Clonal architecture of secondary acute myeloid leukemia. N.Engl. J. Med. 2012, 366:1090-1098.
45. Welch J.S., Ley T.J., Link D.C., Miller C.A., Larson D.E., Koboldt D.C., Wartman L.D., Lamprecht T.L., Liu F., Xia J., et al. The originand evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
46. Williams A.B., Nguyen B., Li L., Brown P., Levis M., Leahy D., Small D. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2013, 27:48-55.
47. Wunderlich M., Chou F.S., Link K.A., Mizukawa B., Perry R.L., Carroll M., Mulloy J.C. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 2010, 24:1785-1788.
48. Wunderlich M., Mizukawa B., Chou F.S., Sexton C., Shrestha M., Saunthararajah Y., Mulloy J.C. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood 2013, 121:e90-e97.